OncoMatch/Clinical Trials/NCT07208981
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
Is NCT07208981 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Orelabrutinib and Zebetuzumab for marginal zone lymphoma(mzl).
Treatment: Orelabrutinib · Zebetuzumab · Lenalidomide · Bendamustine + Rituximab — This is an open-label, multicenter, phase 2, non-randomized study aiming to evaluate the efficacy and safety of orelabrutinib combined with zebetuzumab and lenalidomide or bendamustine combined with rituximab in the treatment of newly diagnosed marginal zone lymphoma (MZL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20-positive)
Histopathologically confirmed CD20-positive marginal zone lymphoma
Disease stage
Required: Stage II 2, IIE, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
absolute neutrophil count ≥1.5×10^9/l, platelets ≥75×10^9/l, hemoglobin ≥75g/l; if accompanied by bone marrow involvement, absolute neutrophil count ≥1.0×10^9/l, platelets ≥50×10^9/l, hemoglobin ≥50g/l
Kidney function
serum creatinine ≤ 1.5 times uln; creatinine clearance rate ≥ 60 ml/min
Liver function
total bilirubin ≤ 1.5 times uln, ast or alt ≤ 2 times uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify